MedTrace Logo

Toxicity and Efficacy Evaluation of Topical Minoxidil in Acne Vulgaris

NCT06108193 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2023-11-03

No results posted yet for this study

Summary

Patients with acne vulgaris (AV) appeared to be a chronic inflammation with a wide range in teenagers and adult. The protocol design is as follows.

The subjects enrolled through inclusion and exclusion criteria will undergo the blood and urine biochemical tests for baseline record. The photos from the subjects will be recorded per day, and the blood and urine biochemical tests will be recorded per week.

Objectives: primary: to test the toxicity of topical minoxidil in treatment of acne vulgaris; second: to evaluate the response and disease control rate in this pilot study.

Measurement: Time to resolution of individual acne lesions (14 days) Monitor of treatment efficacy: number of inflammatory acne lesions counting, time to resolution of individual acne lesion, and degree of acne severity measurement.

Conditions

  • Acne Vulgaris

Interventions

DRUG

topical minoxidil in Acne Vulgaris

Split face: 2% or 5% topical minoxidil solution applied and no treatment Description: Subjects will apply the 2% or 5% topical minoxidil solution to every inflammatory acne facial lesion on one half of the face and no treatment to every inflammatory acne lesion on the other half of the face twice a day for 4 weeks.

Sponsors & Collaborators

  • Chang Gung Memorial Hospital

    lead OTHER

Principal Investigators

  • Cheng-Lung Hsu, Profesor · Chang Gung Memorial Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-11
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06108193 on ClinicalTrials.gov